

# David D Waters

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3729960/publications.pdf>

Version: 2024-02-01

96  
papers

11,362  
citations

136740

32  
h-index

60497

81  
g-index

99  
all docs

99  
docs citations

99  
times ranked

12902  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Torcetrapib in Patients at High Risk for Coronary Events. <i>New England Journal of Medicine</i> , 2007, 357, 2109-2122.	13.9	2,811
2	Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019, 381, 2497-2505.	13.9	1,696
3	Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 49.	3.8	1,586
4	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , 2015, 385, 351-361.	6.3	562
5	Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2014, 64, 485-494.	1.2	512
6	Effects of Hormone Replacement Therapy and Antioxidant Vitamin Supplements on Coronary Atherosclerosis in Postmenopausal Women. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 2432.	3.8	500
7	Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1535-1545.	1.2	305
8	Lipid Treatment Assessment Project 2. <i>Circulation</i> , 2009, 120, 28-34.	1.6	293
9	Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. <i>Aids</i> , 2006, 20, 2275-2283.	1.0	239
10	Body-Weight Fluctuations and Outcomes in Coronary Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1332-1340.	13.9	229
11	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 924-932.	5.2	218
12	Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. <i>American Journal of Cardiology</i> , 2004, 93, 154-158.	0.7	182
13	Effects of Atorvastatin on Stroke in Patients With Unstable Angina or Non-Q-Wave Myocardial Infarction. <i>Circulation</i> , 2002, 106, 1690-1695.	1.6	180
14	Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). <i>European Heart Journal</i> , 2020, 41, 4092-4099.	1.0	174
15	Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy. <i>Journal of the American College of Cardiology</i> , 2013, 61, 148-152.	1.2	160
16	HIV infection and coronary heart disease: mechanisms and management. <i>Nature Reviews Cardiology</i> , 2019, 16, 745-759.	6.1	128
17	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <i>European Heart Journal</i> , 2015, 36, 1536-1546.	1.0	126
18	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. <i>Circulation</i> , 2018, 138, 770-781.	1.6	126

#	ARTICLE	IF	CITATIONS
19	Randomized Double-Blind Comparison of Two Doses of Hirulog With Heparin as Adjunctive Therapy to Streptokinase to Promote Early Patency of the Infarct-Related Artery in Acute Myocardial Infarction. <i>Circulation</i> , 1995, 91, 2132-2139.	1.6	100
20	Myocardial Infarction in the ISCHEMIA Trial. <i>Circulation</i> , 2021, 143, 790-804.	1.6	81
21	Time to Recognize HIV Infection as a Major Cardiovascular Risk Factor. <i>Circulation</i> , 2018, 138, 1113-1115.	1.6	80
22	Safety of High-Dose Atorvastatin Therapy. <i>American Journal of Cardiology</i> , 2005, 96, 69-75.	0.7	67
23	Inflammation, Statin Therapy, and Risk of Stroke After an Acute Coronary Syndrome in the MIRACL Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 142-147.	1.1	65
24	Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial. <i>American Journal of Cardiology</i> , 2017, 119, 379-387.	0.7	58
25	Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004724.	0.9	50
26	Visit-to-visit variability of lipid measurements as predictors of cardiovascular events. <i>Journal of Clinical Lipidology</i> , 2018, 12, 356-366.	0.6	45
27	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. <i>Journal of Clinical Lipidology</i> , 2018, 12, 130-136.	0.6	44
28	Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 486-495.	1.8	44
29	Impact of Female Sex on Lipid Lowering, Clinical Outcomes, and Adverse Effects in Atorvastatin Trials. <i>American Journal of Cardiology</i> , 2015, 115, 447-453.	0.7	43
30	Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers. <i>PLoS ONE</i> , 2014, 9, e114519.	1.1	38
31	Lipid Abnormalities in Persons Living With HIV Infection. <i>Canadian Journal of Cardiology</i> , 2019, 35, 249-259.	0.8	38
32	2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?. <i>American Journal of Medicine</i> , 2016, 129, 384-391.	0.6	37
33	Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials. <i>American Journal of Cardiology</i> , 2014, 113, 2018-2020.	0.7	36
34	Cardiovascular drugs that increase the risk of new-onset diabetes. <i>American Heart Journal</i> , 2014, 167, 421-428.	1.2	30
35	What the Statin Trials Have Taught Us. <i>American Journal of Cardiology</i> , 2006, 98, 129-134.	0.7	29
36	Exploring new indications for statins beyond atherosclerosis: Successes and setbacks. <i>Journal of Cardiology</i> , 2010, 55, 155-162.	0.8	29

#	ARTICLE	IF	CITATIONS
37	Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL). American Journal of Cardiology, 2014, 113, 1378-1382.	0.7	27
38	Cholesterol Lowering. Circulation, 1999, 99, 3215-3217.	1.6	26
39	Effect of Change in Body Weight on Incident Diabetes Mellitus in Patients With Stable Coronary Artery Disease Treated With Atorvastatin (from the Treating to New Targets Study). American Journal of Cardiology, 2014, 113, 1593-1598.	0.7	25
40	Early Statin Therapy in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 54, 1434-1437.	1.2	24
41	High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study). Metabolism: Clinical and Experimental, 2019, 93, 93-99.	1.5	24
42	The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 111.	1.5	22
43	Variations in time to benefit among clinical trials of cholesterol-lowering drugs. Journal of Clinical Lipidology, 2018, 12, 857-862.	0.6	21
44	Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. American Heart Journal, 2020, 222, 157-165.	1.2	21
45	PCSK9 Inhibitors for Statin Intolerance?. JAMA - Journal of the American Medical Association, 2016, 315, 1571.	3.8	16
46	An Evidence-Based Guide to Cholesterol-Lowering Guidelines. Canadian Journal of Cardiology, 2017, 33, 343-349.	0.8	16
47	Body-Weight Fluctuations and Outcomes in Coronary Disease. New England Journal of Medicine, 2017, 377, 94-96.	13.9	15
48	LDL-cholesterol lowering and renal outcomes. Current Opinion in Lipidology, 2015, 26, 195-199.	1.2	14
49	Predicting Prognosis in Acute Coronary Syndromes: Makeover Time for TIMI and GRACE?. Canadian Journal of Cardiology, 2016, 32, 1290-1293.	0.8	14
50	Postscripts From the Post Coronary Artery Bypass Graft Trial. Circulation, 2000, 102, 144-146.	1.6	13
51	Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (from the Treating to New Targets Study). American Journal of Cardiology, 2016, 118, 1275-1281.	0.7	13
52	PCSK9 Inhibition to Reduce Cardiovascular Risk. Circulation Research, 2017, 120, 1537-1539.	2.0	13
53	Statins and safety: applying the results of randomized trials to clinical practice. American Journal of Cardiology, 2003, 92, 692-695.	0.7	12
54	What do the statin trials tell us?. Clinical Cardiology, 2009, 24, 3-7.	0.7	8

#	ARTICLE	IF	CITATIONS
55	Looking for Coronary Disease in Patients With Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2014, 30, 861-863.	0.8	7
56	PCSK9 Inhibition to Lower LDL-Cholesterol and Reduce Cardiovascular Risk. <i>Circulation Research</i> , 2015, 116, 1643-1645.	2.0	7
57	Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003183.	1.6	7
58	Clinical Insights From the Treating to New Targets Trial. <i>Progress in Cardiovascular Diseases</i> , 2009, 51, 487-502.	1.6	6
59	Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study). <i>American Journal of Cardiology</i> , 2016, 118, 494-498.	0.7	6
60	Low-Density-Lipoprotein Cholesterol Goals for Patients With Coronary Disease. <i>Circulation</i> , 2001, 104, 2635-2637.	1.6	6
61	Statin-centric versus low-density lipoprotein-centric approach for atherosclerotic cardiovascular disease prevention: a Singapore perspective. <i>Singapore Medical Journal</i> , 2016, 57, 360-367.	0.3	6
62	The Curse of Target Lesion Calcification. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1855-1856.	1.2	5
63	The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1209-1211.	0.8	4
64	The Rise and Fall of Tuberculosis and Atherosclerosis: First There Is a Mountain. <i>Canadian Journal of Cardiology</i> , 2017, 33, 295-297.	0.8	4
65	Lipids, inflammation, and chronic kidney disease: a SHARP perspective. <i>Kidney International</i> , 2018, 93, 784-786.	2.6	4
66	Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now. <i>Canadian Journal of Cardiology</i> , 2019, 35, 590-597.	0.8	4
67	Will Colchicine Soon Be Part of Primary and Secondary Cardiovascular Prevention?. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1697-1699.	0.8	4
68	Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcatrapib. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003219.	1.6	4
69	The Past and Future of Heart Institutes: Having Moved Beyond the One-Trick Pony. <i>Canadian Journal of Cardiology</i> , 2014, 30, S478-S482.	0.8	3
70	Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	3
71	Improving Statin Noncompliance: If You Build It, Will They Come?. <i>Canadian Journal of Cardiology</i> , 2019, 35, 813-815.	0.8	3
72	Utility of Biomarkers and Imaging in the Development of Drugs for the Treatment of Coronary Atherosclerosis. <i>Canadian Journal of Cardiology</i> , 2012, 28, 687-692.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Meta-Analyses of Statin Trials. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2100-2101.	1.2	2
74	Taking Hockey to Heart: Potential Coronary Risks of Watching Exciting Games. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1517-1519.	0.8	2
75	Timing of statin dose: a systematic review and meta-analysis of randomized clinical trials. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e319-e322.	0.8	2
76	Tribulations of Recent Cardiology Trials, the Audacity of Hope, and HOPE-3. <i>Canadian Journal of Cardiology</i> , 2016, 32, 275-277.	0.8	1
77	Are Cholesterol Treatment Targets a Deterrent to Optimal Lipid-Lowering Therapy?. <i>JAMA Cardiology</i> , 2017, 2, 1392.	3.0	1
78	RE: Praluent (Alirocumab)-Induced Renal Injury. <i>Journal of Pharmacy Practice</i> , 2018, 31, 138-139.	0.5	1
79	Notes From Cardiology Clinic: When Our Responsibilities Extend Beyond the Patient. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1294-1295.	0.8	1
80	Introduction to Cardiovascular Issues in HIV. <i>Canadian Journal of Cardiology</i> , 2019, 35, 233-234.	0.8	1
81	Changing the Face of Cardiovascular Trial Participation: Moving Beyond Middle-Aged White Guys. <i>CJC Open</i> , 2021, 3, S1-S3.	0.7	1
82	Performance Deficiencies in the Treatment of ST-Elevation Myocardial Infarction in Québec: It's But a Part We See, and Not a Whole. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1294.e5-1294.e7.	0.8	0
83	Notes From Cardiology Clinic: Woman, Lost During Follow-up. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1435-1436.	0.8	0
84	Notes From Cardiology Clinic: The Patients We Dislike. <i>Canadian Journal of Cardiology</i> , 2020, 36, 453-454.	0.8	0
85	When Diastole Lets You Down: Clinical Relevance of a Widened Pulse Pressure. <i>Canadian Journal of Cardiology</i> , 2020, 36, 593-595.	0.8	0
86	Erratum to "Notes From Cardiology Clinic: The Patients We Dislike". <i>Canadian Journal of Cardiology</i> , 2020, 36, 965.	0.8	0
87	Notes From Cardiology Clinic: Health Care Heroine, Unpaid and Unappreciated. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1178-1179.	0.8	0
88	Notes From Cardiology Clinic: The Heartbreaking Risk Factor We Overlook. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1975-1976.	0.8	0
89	Notes From the Cardiology Clinic: Facing Down the Dragons of Health Anxiety. <i>Canadian Journal of Cardiology</i> , 2020, 36, 820-821.	0.8	0
90	Notes From Cardiology Clinic: Brittle Bones and Blue Sclerae. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1009-1010.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Notes From Cardiology Clinic: Trouble for Tongans. Canadian Journal of Cardiology, 2021, 37, 355-356.	0.8	0
92	Notes From Cardiology Clinic: Mitral Stenosis and Racial Discordance. Canadian Journal of Cardiology, 2021, 37, 833-834.	0.8	0
93	Notes From Cardiology Clinic: Cinderella's Electronic Medical Record. Canadian Journal of Cardiology, 2021, 37, 1689-1690.	0.8	0
94	Usefulness of Angina to Guide Revascularization Decisions. Circulation, 2021, 144, 524-527.	1.6	0
95	Notes From Cardiology Clinic: You Can't Ride With the Cops, But Cheer for the Robbers. Canadian Journal of Cardiology, 2021, 37, 1151-1152.	0.8	0
96	Inflammation in Cardiovascular Disease: From Basic Concepts to Clinical Application. International Journal of Cardiovascular Sciences, 2020, , .	0.0	0